US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SMITH-MIDLAND CORP

30.03

-0.2400-0.79%

Pre-market: 29.51-0.5200-1.73%04:09 EDT

Volume:6.43K

Turnover:191.02K

Market Cap:159.27M

PE:24.62

High:30.19

Open:30.19

Low:29.31

Close:30.27

Loading ...

Overview Company News Filings

Is SiTime Corporation (SITM) One of the Best Mid-Cap Growth Stocks to Buy According to Analysts?

Onto Innovation Inc. (ONTO): One of the Best Mid-Cap Growth Stocks to Buy According to Analysts

Uranium Energy Corp. (UEC): Among the Best Mid-Cap Growth Stocks to Buy According to Analysts

Is Legend Biotech (LEGN) the Best Mid-Cap Growth Stock to Buy According to Analysts?

Those who invested in Smith-Midland (NASDAQ:SMID) five years ago are up 498%

Simply Wall St.

SouthernSun SMID Cap Strategy’s Top Contributor: SEI Investments Company (SEIC)

Match Group participates in a conference call with JPMorgan

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Here’s Why Polen US SMID Company Growth Strategy Added Insight Enterprises (NSIT) to its Portfolio

Polen US SMID Company Growth Strategy Sold Alarm.com Holdings (ALRM) Despite High-Quality Assessment

Polen US SMID Company Growth Strategy Sold its Unsuccessful Investment in Fox Factory Holding Corp. (FOXF) in Q4

Here’s Why Polen US SMID Company Growth Strategy Exited Euronet Worldwide (EEFT)

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SMID/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SMID","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SMID\",,,,,undefined,":{"symbol":"SMID","market":"US","secType":"STK","nameCN":"SMITH-MIDLAND CORP","latestPrice":30.03,"timestamp":1745524800000,"preClose":30.27,"halted":0,"volume":6426,"hourTrading":{"tag":"盘前","latestPrice":29.51,"preClose":30.03,"latestTime":"04:09 EDT","volume":2,"amount":58.83,"timestamp":1745568573573},"delay":0,"floatShares":4546993,"shares":5303606,"eps":1.219701,"marketStatus":"Pre-Mkt","change":-0.24,"latestTime":"04-25 05:51:03 EDT","open":30.19,"high":30.19,"low":29.31,"amount":191018.4177,"amplitude":0.029072,"askPrice":34,"askSize":3,"bidPrice":12.08,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.219701,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745587800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":30.03,"preHourTrading":{"tag":"盘前","latestPrice":29.51,"preClose":30.03,"latestTime":"04:09 EDT","volume":2,"amount":58.83,"timestamp":1745568573573},"postHourTrading":{"tag":"盘后","latestPrice":30.03,"preClose":30.03,"latestTime":"16:05 EDT","volume":296,"amount":8893.94,"timestamp":1745525113904},"volumeRatio":0.9257231948832038},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SMID\",,,,,undefined,":{"symbol":"SMID","floatShares":4546993,"roa":"8.62%","roe":"17.55%","lyrEps":0.151198,"volumeRatio":0.9257231948832038,"shares":5303606,"dividePrice":0,"high":30.19,"amplitude":0.029072,"preClose":30.27,"low":29.31,"week52Low":25.0301,"pbRate":"3.95","psRate":"2.09","week52High":51.96,"institutionHeld":0.6309,"latestPrice":30.03,"committee":0.941748,"eps":1.219701,"divideRate":0,"volume":6426,"delay":0,"ttmEps":1.219701,"open":30.19,"prevYearClose":44.46,"prevWeekClose":29.61,"prevMonthClose":31.07,"prevQuarterClose":31.07,"fiveDayClose":29.86,"twentyDayClose":34.15,"sixtyDayClose":40.86},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SMID\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2511257163","title":"Is SiTime Corporation (SITM) One of the Best Mid-Cap Growth Stocks to Buy According to Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511257163","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511257163?lang=en_us&edition=fundamental","pubTime":"2025-02-14 03:19","pubTimestamp":1739474356,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Mid-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where SiTime Corporation  stands against other best mid-cap growth stocks to buy according to analysts.Investing in mid-cap growth stocks has long been a favoured strategy for investors looking to strike a balance between the stability of large-cap companies and the high-growth potential of smaller firms. Mid-cap companies, typically defined as those with market capitalizations between $2 billion and $10 billion, occupy that unique space in the market. They are less risky than small-caps, established enough to have proven business models and good access to capital markets, and to top it all, still have ample room for expansion. This combination allows them to swiftly adapt to market changes and capitalize on emerging opportunities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sitime-corporation-sitm-one-best-191916136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","USAW.SI","MEMS","TQQQ","USJW.SI","QID","SQQQ","LU1878469433.USD","BK4141","QLD","NVIW.SI","BK4011","NQmain","TSYW.SI","SITM","MNQmain","SMID",".IXIC"],"gpt_icon":1},{"id":"2511716395","title":"Onto Innovation Inc. (ONTO): One of the Best Mid-Cap Growth Stocks to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2511716395","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511716395?lang=en_us&edition=fundamental","pubTime":"2025-02-14 03:16","pubTimestamp":1739474178,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Mid-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where Onto Innovation Inc.  stands against other best mid-cap growth stocks to buy according to analysts.Investing in mid-cap growth stocks has long been a favoured strategy for investors looking to strike a balance between the stability of large-cap companies and the high-growth potential of smaller firms. Mid-cap companies, typically defined as those with market capitalizations between $2 billion and $10 billion, occupy that unique space in the market. They are less risky than small-caps, established enough to have proven business models and good access to capital markets, and to top it all, still have ample room for expansion. This combination allows them to swiftly adapt to market changes and capitalize on emerging opportunities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onto-innovation-inc-onto-one-191618927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065731478.USD","BK4547","BK4147","LU0566484027.USD","ONTO","LU1559883803.SGD","BK4011","SMID"],"gpt_icon":1},{"id":"2511226579","title":"Uranium Energy Corp. (UEC): Among the Best Mid-Cap Growth Stocks to Buy According to Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2511226579","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511226579?lang=en_us&edition=fundamental","pubTime":"2025-02-14 03:13","pubTimestamp":1739474013,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Mid-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where Uranium Energy Corp.  stands against other best mid-cap growth stocks to buy according to analysts.Investing in mid-cap growth stocks has long been a favoured strategy for investors looking to strike a balance between the stability of large-cap companies and the high-growth potential of smaller firms. Mid-cap companies, typically defined as those with market capitalizations between $2 billion and $10 billion, occupy that unique space in the market. They are less risky than small-caps, established enough to have proven business models and good access to capital markets, and to top it all, still have ample room for expansion. This combination allows them to swiftly adapt to market changes and capitalize on emerging opportunities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/uranium-energy-corp-uec-among-191333796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMID","UEC","BK4606","BK4156","BK4011"],"gpt_icon":0},{"id":"2511794915","title":"Is Legend Biotech (LEGN) the Best Mid-Cap Growth Stock to Buy According to Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511794915","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511794915?lang=en_us&edition=fundamental","pubTime":"2025-02-14 03:06","pubTimestamp":1739473578,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Mid-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where Legend Biotech Corporation  stands against other best mid-cap growth stocks to buy according to analysts.Investing in mid-cap growth stocks has long been a favoured strategy for investors looking to strike a balance between the stability of large-cap companies and the high-growth potential of smaller firms. Mid-cap companies, typically defined as those with market capitalizations between $2 billion and $10 billion, occupy that unique space in the market. They are less risky than small-caps, established enough to have proven business models and good access to capital markets, and to top it all, still have ample room for expansion. This combination allows them to swiftly adapt to market changes and capitalize on emerging opportunities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/legend-biotech-legn-best-mid-190618168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMID","MNQmain","PSQ","BK4011","LEGN","SQQQ","BK4139","NVIW.SI","BK4505","USJW.SI","USAW.SI","NQmain","BK4585","TQQQ","QLD","TSYW.SI",".IXIC","QID","BK4588"],"gpt_icon":1},{"id":"2511581311","title":"Those who invested in Smith-Midland (NASDAQ:SMID) five years ago are up 498%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511581311","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511581311?lang=en_us&edition=fundamental","pubTime":"2025-02-13 03:19","pubTimestamp":1739387989,"startTime":"0","endTime":"0","summary":"For many, the main point of investing in the stock market is to achieve spectacular returns. While the best companies are hard to find, but they can generate massive returns over long periods. To wit, the Smith-Midland Corporation  share price has soared 498% over five years. If that doesn't get you thinking about long term investing, we don't know what will. In the last week shares have slid back 4.5%.With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share  with the share price.During five years of share price growth, Smith-Midland achieved compound earnings per share  growth of 24% per year. This EPS growth is slower than the share price grow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/those-invested-smith-midland-nasdaq-191949632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMID","LU2095319765.USD","PSQ","IE00B3QW5Z07.USD","BK4585","USAW.SI","QID","BK4112","LU2210149790.SGD","BK4011","TQQQ","NDAQ","TSYW.SI","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","NVIW.SI","BK4588","SQQQ","MNQmain","IE00B64PRP62.GBP",".IXIC","QLD","NQmain","USJW.SI"],"gpt_icon":1},{"id":"2509747594","title":"SouthernSun SMID Cap Strategy’s Top Contributor: SEI Investments Company (SEIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509747594","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509747594?lang=en_us&edition=fundamental","pubTime":"2025-02-07 22:52","pubTimestamp":1738939966,"startTime":"0","endTime":"0","summary":"In its fourth quarter 2024 investor letter, SouthernSun SMID Cap Strategy emphasized stocks such as SEI Investments Company . SEI Investments Company  is a publicly owned asset management holding company. The one-month return SEI Investments Company  was 9.16%, and its shares gained 29.39% of their value over the last 52 weeks. On February 6, 2024, SEI Investments Company  stock closed at $86.24 per share, with a market capitalization of $10.939 billion.SEI Investments Company  is not on our list of30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held SEI Investments Company  at the end of the third quarter which was 30 in the previous quarter. SEI Investments Company had an exceptional fourth quarter, with $38 million in sales","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/southernsun-smid-cap-strategy-top-145246381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SEI","USAW.SI","BK4595","IE00B19Z4B17.USD","USJW.SI","SEIC","BK4588","BK4600","TSYW.SI","BK4596","MNQmain","BK4023","BK4135","IE00B66KJ199.SGD","BK4585","IE0031619046.USD",".IXIC","NQmain","IE00B7SZL793.SGD","NVIW.SI","SMID","PSQ","BK4179","QID","QLD","TQQQ","SQQQ","BK4516"],"gpt_icon":1},{"id":"2509620003","title":"Match Group participates in a conference call with JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2509620003","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509620003?lang=en_us&edition=fundamental","pubTime":"2025-02-07 02:35","pubTimestamp":1738866927,"startTime":"0","endTime":"0","summary":"Internet SMID & Video Games Analyst Carpenter holds a conference call with CFO Bailey on February 7 at 11:15 am hosted by JPMorgan. Published first...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/match-group-participates-in-a-conference-call-with-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/match-group-participates-in-a-conference-call-with-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4011","LU0106831901.USD","LU1720051017.SGD","LU0203347892.USD","LU0215105999.USD","LU0240877869.USD","LU1988902786.USD","LU2505996681.GBP","LU2552382132.HKD","LU1496350171.SGD","LU0256863811.USD","LU0251132253.USD","LU1064131342.USD","LU1670628061.USD","LU0211326839.USD","JPM","LU0211327993.USD","LU1084165304.USD","LU1244550577.SGD","LU1917777945.USD","LU1720051108.HKD","LU2430703178.SGD","LU1668664300.SGD","BK4549","IE00B3S45H60.SGD","LU1119994496.HKD","LU0203345920.USD","LU0971096721.USD","MTCH","LU2237443549.SGD","IE00BJTD4V19.USD","LU0205194284.USD","LU0211331839.USD","LU0170899867.USD","LU1032466523.USD","LU1914381329.SGD","LU1894683264.USD","BK4550","SMID","IE00BKVL7J92.USD","LU0070302665.USD","LU2237443978.SGD","LU2023250504.SGD","SG9999002224.SGD","LU2237443895.HKD","LU1496350502.SGD","BK4077","IE00BDRTCR15.USD","BK4534","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2508178097","title":"Anaptys to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2508178097","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508178097?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:15","pubTimestamp":1738617300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb. 03, 2025  -- AnaptysBio, Inc. , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT.Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anaptys-present-guggenheim-smid-cap-211500699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANAB","BK4139","BK4011","SMID"],"gpt_icon":0},{"id":"2508148418","title":"Here’s Why Polen US SMID Company Growth Strategy Added Insight Enterprises (NSIT) to its Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2508148418","media":"Insider Monkey","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508148418?lang=en_us&edition=fundamental","pubTime":"2025-02-03 21:22","pubTimestamp":1738588971,"startTime":"0","endTime":"0","summary":"Polen Capital, an investment management company, released its “Polen US SMID Company Growth Strategy” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. SMID cap stocks initially rose by more than 10% following November's U.S. Presidential election, in another volatile quarter. However, they relinquished nearly all of those gains in December, as the U.S. Federal Reserve signaled that interest rate cuts would occur more slowly than anticipated, with reductions expected to start in 2025. Against this backdrop, the fund returned 3.0% gross, and 2.7% net of fees compared to the Russell 2500 Growth Index return of 2.4%. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2024.Polen US SMID Company Growth Strategy stated the following regarding Insight Enterprises, Inc.  in its Q4 2024 investor letter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-polen-us-smid-company-132251308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NSIT","USAW.SI","TSYW.SI","BK4140","USJW.SI","QID","NQmain","NVIW.SI","PSQ","TQQQ","QLD",".IXIC","INAQU","SMID","SQQQ","MNQmain"],"gpt_icon":1},{"id":"2508975148","title":"Polen US SMID Company Growth Strategy Sold Alarm.com Holdings (ALRM) Despite High-Quality Assessment","url":"https://stock-news.laohu8.com/highlight/detail?id=2508975148","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508975148?lang=en_us&edition=fundamental","pubTime":"2025-02-03 21:04","pubTimestamp":1738587844,"startTime":"0","endTime":"0","summary":"Polen Capital, an investment management company, released its “Polen US SMID Company Growth Strategy” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. SMID cap stocks initially rose by more than 10% following November's U.S. Presidential election, in another volatile quarter. However, they relinquished nearly all of those gains in December, as the U.S. Federal Reserve signaled that interest rate cuts would occur more slowly than anticipated, with reductions expected to start in 2025. Against this backdrop, the fund returned 3.0% gross, and 2.7% net of fees compared to the Russell 2500 Growth Index return of 2.4%. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2024.Polen US SMID Company Growth Strategy stated the following regarding Alarm.com Holdings, Inc.  in its Q4 2024 investor letter:. Inanother article, we discussed Alarm.com Holdings, Inc.  and shared The Brown Capital Management Small Company Fund's views on t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polen-us-smid-company-growth-130404955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","MNQmain","USJW.SI",".IXIC","USAW.SI","PSQ","QID","ALRM","TQQQ","QLD","TSYW.SI","NVIW.SI","NQmain","SMID","SQQQ"],"gpt_icon":1},{"id":"2508110404","title":"Polen US SMID Company Growth Strategy Sold its Unsuccessful Investment in Fox Factory Holding Corp. (FOXF) in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2508110404","media":"Insider Monkey","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508110404?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:56","pubTimestamp":1738587391,"startTime":"0","endTime":"0","summary":"Polen Capital, an investment management company, released its “Polen US SMID Company Growth Strategy” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. SMID cap stocks initially rose by more than 10% following November's U.S. Presidential election, in another volatile quarter. However, they relinquished nearly all of those gains in December, as the U.S. Federal Reserve signaled that interest rate cuts would occur more slowly than anticipated, with reductions expected to start in 2025. Against this backdrop, the fund returned 3.0% gross, and 2.7% net of fees compared to the Russell 2500 Growth Index return of 2.4%. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2024.Polen US SMID Company Growth Strategy stated the following regarding Fox Factory Holding Corp.  in its Q4 2024 investor letter:. Inanother article, we discussed Fox Factory Holding Corp.  and shared Conestoga Capital Advisors' views on the company in the pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polen-us-smid-company-growth-125631224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","USJW.SI",".IXIC","FOXF","IE00B64QTZ34.USD","USAW.SI","BK4124","PSQ","QID","TQQQ","QLD","TSYW.SI","NVIW.SI","NQmain","SMID","SQQQ"],"gpt_icon":1},{"id":"2508104751","title":"Here’s Why Polen US SMID Company Growth Strategy Exited Euronet Worldwide (EEFT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2508104751","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508104751?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:53","pubTimestamp":1738587238,"startTime":"0","endTime":"0","summary":"Polen Capital, an investment management company, released its “Polen US SMID Company Growth Strategy” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. SMID cap stocks initially rose by more than 10% following November's U.S. Presidential election, in another volatile quarter. However, they relinquished nearly all of those gains in December, as the U.S. Federal Reserve signaled that interest rate cuts would occur more slowly than anticipated, with reductions expected to start in 2025. Against this backdrop, the fund returned 3.0% gross, and 2.7% net of fees compared to the Russell 2500 Growth Index return of 2.4%. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2024.Polen US SMID Company Growth Strategy stated the following regarding Euronet Worldwide, Inc.  in its Q4 2024 investor letter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-polen-us-smid-company-125358727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","QLD","TSYW.SI","USAW.SI","SMID","NVIW.SI","BK4227","PSQ","TQQQ","EEFT","BK4106",".IXIC","NQmain","USJW.SI","MNQmain","QID"],"gpt_icon":1},{"id":"2507295793","title":"Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507295793","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507295793?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 31, 2025  -- Erasca, Inc.,a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/erasca-present-guggenheim-securities-smid-130000798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","ERAS","SMID","BK4011"],"gpt_icon":0},{"id":"2507637603","title":"Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507637603","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507637603?lang=en_us&edition=fundamental","pubTime":"2025-01-31 05:05","pubTimestamp":1738271100,"startTime":"0","endTime":"0","summary":"SAN CARLOS, Calif., Jan.  30, 2025  (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/30/3018412/0/en/Vaxcyte-to-Present-at-the-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4011","LU0053671581.USD","PCVX","IE0009354923.USD","BK4139","SMID"],"gpt_icon":0},{"id":"2507603464","title":"Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507603464","media":"Newsfile","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507603464?lang=en_us&edition=fundamental","pubTime":"2025-01-31 05:00","pubTimestamp":1738270800,"startTime":"0","endTime":"0","summary":"Philadelphia, Pennsylvania and Oxford, United Kingdom-- - Adaptimmune Therapeutics plc , a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February.Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. EST. Adaptimmune ContactInvestor RelationsJuli P. Miller, Ph.D. - VP, Corporate Affairs and Investor RelationsT : +1 215 825 9310M : +1 215 460 8920Juli.Miller@adaptimmune.com. Media RelationsDana Lynch, Senior Director of Corporate CommunicationsM: +1 267 990 1217Dana.Lynch@adaptimmune.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adaptimmune-participate-guggenheim-securities-smid-210000309.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adaptimmune-participate-guggenheim-securities-smid-210000309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4011","SMID","BK4139","ADAP"],"gpt_icon":0},{"id":"2507647725","title":"ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507647725","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507647725?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:15","pubTimestamp":1738239300,"startTime":"0","endTime":"0","summary":"LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:00 p.m. ET.A live webcast of the presentation will be available via the Events & Presentations page in the IR section of the ADC Therapeutics website. A replay of the webcast will be available for approximately 30 days.About ADC TherapeuticsADC Therapeutics  is a commercial-stage global leader and pioneer in the field of antibody drug conjugates . The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.ZYNLONTA is a registered trademark of ADC Therapeutics SA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adc-therapeutics-participate-guggenheim-smid-121500438.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-participate-guggenheim-smid-121500438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4080","SMID","BK4139","ADC","BK4231","BK4505","BK4011","ADCT"],"gpt_icon":0},{"id":"2507664251","title":"Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507664251","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507664251?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"BOSTON, Jan. 30, 2025  -- Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET.Investor Contact: Daniella Beckman Chief Financial Officer, Tango TherapeuticsIR@tangotx.com. Media Contact: Daniella Beckman Chief Financial Officer, Tango Therapeuticsmedia@tangotx.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tango-therapeutics-present-guggenheim-smid-120000359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SMID","TNGX","BK4011","LENZ"],"gpt_icon":0},{"id":"2507642861","title":"EyePoint to Present at Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507642861","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507642861?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Jan. 30, 2025  -- EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET.Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert Eto potentially improve outcomes in serious retinal diseases. The proven Durasertdrug delivery technology has been safely administered to thousands of patient eyes across fourU.S.FDA approved products.EyePoint Pharmaceuticalsis headquartered inWatertown, Massachusetts.DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eyepoint-present-guggenheim-smid-cap-120000292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4573","LU1951200564.SGD","BK4512","SMID","BK4534","EYPT","LU0109394709.USD","IE0004445239.USD","LU1242518931.SGD","LU1242518857.USD","LU1880398471.USD","BK4532","LU2250418816.HKD","LU1803068979.SGD","LU2054465674.USD","LU0198837287.USD","LU0823434740.USD","LU1951198990.SGD","LU0642271901.SGD","LU0889565916.HKD","LU1988902786.USD","IE0009356076.USD","LU0889565833.HKD","LU2458330243.SGD","LU1852331112.SGD","BK4011","LU1316542783.SGD","LU0719512351.SGD","LU0823421416.USD","LU0109392836.USD","LU0082616367.USD","BK4529","IE00B5949003.HKD","LU2098885051.SGD","BK4007","BK4141","BK4588","LU1064131342.USD","LU0320765992.SGD","LU0979878070.USD","IE00BMPRXN33.USD","LU1923623000.USD","LU0056508442.USD","BK4575","LU0390134368.USD","LU1303367103.USD","LU2264538146.SGD","LU0081259029.USD"],"gpt_icon":1},{"id":"2507642708","title":"Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507642708","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507642708?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan.  30, 2025  (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that J","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/30/3017859/0/en/Beam-Therapeutics-to-Participate-in-Guggenheim-SMID-Cap-Biotech-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4011","SMID","LENZ"],"gpt_icon":0},{"id":"2507642058","title":"Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2507642058","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507642058?lang=en_us&edition=fundamental","pubTime":"2025-01-30 20:00","pubTimestamp":1738238400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan. 30, 2025  -- Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference, being held in New York on February 5 and 6, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-participate-fireside-chat-120000714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CGEM","BK4011","BK4139","SMID"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":79,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SMID\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"SMID","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":0.59},{"market":"US","date":"2024-08-14","symbol":"SMID","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":0.37},{"market":"US","date":"2024-06-11","symbol":"SMID","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1718078400000,"reportTimeType":"post","actualEps":0.21},{"market":"US","date":"2024-05-23","symbol":"SMID","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1716436800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2023-11-09","symbol":"SMID","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1699506000000,"reportTimeType":"","actualEps":0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SMID\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-16","recordDate":"2015-12-18","paymentDate":"2015-12-30","value":0.04,"currency":"USD"},{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-13","value":0.01,"currency":"USD"},{"executeDate":"2018-12-18","recordDate":null,"paymentDate":null,"value":0.055,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":null,"value":0.055,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SMID\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SMID\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SMID","date":"2025-04-24","current":24.668124,"percent":0.026059,"low":20.854222,"twenty":32.391017,"median":40.369977,"eighty":353.20593,"high":430.955547,"avg":150.932407,"sd":152.585294,"marketCap":160540153},"quantilePoints":[{"date":"2024-01-05","current":371.443946,"twenty":371.443946,"median":371.443946,"eighty":371.443946,"marketCap":211351605},{"date":"2024-01-12","current":364.577223,"twenty":364.394111,"median":366.316793,"eighty":371.443946,"marketCap":207444440},{"date":"2024-01-19","current":350.01977,"twenty":354.542651,"median":364.485667,"eighty":368.733879,"marketCap":199161249},{"date":"2024-01-26","current":383.98716,"twenty":357.893612,"median":365.950568,"eighty":375.14282,"marketCap":218488694},{"date":"2024-02-02","current":364.668779,"twenty":358.122503,"median":366.774575,"eighty":374.923085,"marketCap":207496535},{"date":"2024-02-09","current":411.911835,"twenty":362.526361,"median":368.056362,"eighty":380.398154,"marketCap":234377834},{"date":"2024-02-16","current":407.334019,"twenty":364.210998,"median":373.961745,"eighty":391.275043,"marketCap":231773057},{"date":"2024-02-23","current":402.481534,"twenty":364.503978,"median":375.838648,"eighty":397.766385,"marketCap":229011993},{"date":"2024-03-01","current":419.602564,"twenty":364.632157,"median":378.676895,"eighty":406.857926,"marketCap":238753859},{"date":"2024-03-08","current":288.310817,"twenty":361.574176,"median":376.708433,"eighty":406.436768,"marketCap":164048855},{"date":"2024-03-15","current":318.707511,"twenty":352.601658,"median":374.831529,"eighty":405.722628,"marketCap":181344574},{"date":"2024-03-22","current":406.143787,"twenty":354.487717,"median":375.838648,"eighty":405.649383,"marketCap":231095815},{"date":"2024-03-28","current":402.481534,"twenty":355.055367,"median":376.708433,"eighty":405.814184,"marketCap":229011993},{"date":"2024-04-05","current":402.847761,"twenty":356.932271,"median":379.500902,"eighty":406.986105,"marketCap":229220376},{"date":"2024-04-12","current":373.458185,"twenty":360.62199,"median":381.423584,"eighty":407.297396,"marketCap":212497707},{"date":"2024-04-19","current":343.610828,"twenty":356.932271,"median":377.852888,"eighty":406.986105,"marketCap":195514561},{"date":"2024-04-26","current":339.033012,"twenty":351.484671,"median":375.838648,"eighty":406.491701,"marketCap":192909784},{"date":"2024-05-03","current":338.8499,"twenty":338.923145,"median":373.458185,"eighty":406.253655,"marketCap":192805593},{"date":"2024-05-10","current":307.629199,"twenty":336.982151,"median":370.253714,"eighty":405.814184,"marketCap":175041014},{"date":"2024-05-17","current":335.096091,"twenty":332.679005,"median":367.781694,"eighty":404.330972,"marketCap":190669676},{"date":"2024-05-24","current":315.77771,"twenty":332.679005,"median":366.774574,"eighty":402.70127,"marketCap":179677517},{"date":"2024-05-31","current":243.243577,"twenty":329.675959,"median":365.675899,"eighty":402.481534,"marketCap":193378644},{"date":"2024-06-07","current":221.387574,"twenty":320.373836,"median":364.577223,"eighty":402.371667,"marketCap":176003121},{"date":"2024-06-14","current":103.82899,"twenty":307.629199,"median":364.394111,"eighty":401.932197,"marketCap":193329580},{"date":"2024-06-21","current":92.953443,"twenty":301.439992,"median":358.717619,"eighty":401.199747,"marketCap":173079310},{"date":"2024-06-28","current":78.505306,"twenty":301.000521,"median":355.742039,"eighty":400.888455,"marketCap":146176879},{"date":"2024-07-05","current":73.651635,"twenty":287.76148,"median":354.322916,"eighty":400.37574,"marketCap":137139344},{"date":"2024-07-12","current":83.612948,"twenty":243.243577,"median":351.255781,"eighty":396.026815,"marketCap":155687309},{"date":"2024-07-15","current":83.076786,"twenty":239.219562,"median":350.01977,"eighty":395.541567,"marketCap":154688976},{"date":"2024-08-02","current":95.239183,"twenty":237.221196,"median":347.181524,"eighty":395.056318,"marketCap":177335358},{"date":"2024-08-09","current":82.709939,"twenty":225.706685,"median":343.33616,"eighty":393.344215,"marketCap":154005907},{"date":"2024-08-16","current":36.655516,"twenty":102.484673,"median":340.269023,"eighty":392.11736,"marketCap":169531762},{"date":"2024-08-23","current":36.093702,"twenty":98.427931,"median":338.758344,"eighty":390.634149,"marketCap":166933371},{"date":"2024-08-30","current":40.221317,"twenty":87.349146,"median":337.018774,"eighty":388.253685,"marketCap":186023592},{"date":"2024-09-06","current":34.14455,"twenty":83.392839,"median":334.729866,"eighty":385.049213,"marketCap":157918545},{"date":"2024-09-13","current":37.435177,"twenty":80.491925,"median":332.349402,"eighty":384.426631,"marketCap":173137693},{"date":"2024-09-20","current":43.764187,"twenty":78.211828,"median":329.785826,"eighty":383.858981,"marketCap":202409364},{"date":"2024-09-27","current":39.584976,"twenty":74.057989,"median":329.053374,"eighty":382.577192,"marketCap":183080516},{"date":"2024-10-04","current":35.715337,"twenty":43.489013,"median":317.242611,"eighty":379.336101,"marketCap":165183434},{"date":"2024-10-11","current":39.670968,"twenty":41.202772,"median":307.629199,"eighty":378.512094,"marketCap":183478229},{"date":"2024-10-18","current":37.607161,"twenty":40.301576,"median":302.822492,"eighty":377.688086,"marketCap":173933119},{"date":"2024-10-25","current":36.804569,"twenty":39.673261,"median":300.945587,"eighty":376.900701,"marketCap":170221131},{"date":"2024-10-31","current":38.742255,"twenty":39.338466,"median":288.310817,"eighty":376.387986,"marketCap":179182929},{"date":"2024-11-08","current":41.562792,"twenty":39.269672,"median":262.6784,"eighty":375.289311,"marketCap":192227913},{"date":"2024-11-15","current":27.789331,"twenty":39.269672,"median":243.243577,"eighty":374.831529,"marketCap":180852964},{"date":"2024-11-22","current":36.655839,"twenty":38.673461,"median":236.428563,"eighty":373.458185,"marketCap":238556197},{"date":"2024-11-29","current":40.013376,"twenty":38.554219,"median":226.952073,"eighty":373.165205,"marketCap":260407054},{"date":"2024-12-06","current":38.799121,"twenty":38.554219,"median":221.387574,"eighty":371.773549,"marketCap":252504681},{"date":"2024-12-13","current":40.518637,"twenty":38.574497,"median":102.708726,"eighty":369.539575,"marketCap":263695290},{"date":"2024-12-20","current":35.669766,"twenty":38.301976,"median":99.671306,"eighty":368.257786,"marketCap":232138834},{"date":"2024-12-27","current":38.090127,"twenty":38.160211,"median":97.750675,"eighty":367.891561,"marketCap":247890544},{"date":"2025-01-03","current":35.8735,"twenty":38.026802,"median":93.122757,"eighty":367.708449,"marketCap":233464736},{"date":"2025-01-10","current":32.41002,"twenty":37.861697,"median":83.612948,"eighty":367.561959,"marketCap":210924410},{"date":"2025-01-17","current":33.363496,"twenty":37.645079,"median":83.401305,"eighty":367.159111,"marketCap":217129629},{"date":"2025-01-24","current":33.550931,"twenty":37.458108,"median":82.893362,"eighty":366.13368,"marketCap":218349459},{"date":"2025-01-31","current":33.070118,"twenty":37.40078,"median":80.480637,"eighty":365.950568,"marketCap":215220331},{"date":"2025-02-07","current":30.584563,"twenty":36.919225,"median":78.67462,"eighty":365.40123,"marketCap":199044333},{"date":"2025-02-14","current":30.454173,"twenty":36.655516,"median":76.445317,"eighty":364.668779,"marketCap":198195756},{"date":"2025-02-21","current":30.242289,"twenty":36.093702,"median":75.683404,"eighty":364.595534,"marketCap":196816818},{"date":"2025-02-28","current":27.715986,"twenty":35.893058,"median":73.313007,"eighty":364.430733,"marketCap":180375640},{"date":"2025-03-07","current":27.618194,"twenty":35.775708,"median":43.420219,"eighty":364.394111,"marketCap":179739207},{"date":"2025-03-14","current":26.526179,"twenty":35.319343,"median":42.738016,"eighty":363.66166,"marketCap":172632375},{"date":"2025-03-21","current":26.884751,"twenty":34.845366,"median":42.227797,"eighty":359.669805,"marketCap":174965961},{"date":"2025-03-28","current":28.661313,"twenty":34.002405,"median":41.774906,"eighty":356.337155,"marketCap":186527823},{"date":"2025-04-04","current":22.402601,"twenty":33.539522,"median":41.195893,"eighty":354.826476,"marketCap":145796128},{"date":"2025-04-11","current":23.902084,"twenty":33.350457,"median":40.914787,"eighty":354.37785,"marketCap":155554763},{"date":"2025-04-17","current":24.334,"twenty":32.876164,"median":40.680642,"eighty":353.93838,"marketCap":158365675},{"date":"2025-04-24","current":24.668124,"twenty":32.391017,"median":40.369977,"eighty":353.20593,"marketCap":160540153}],"updateTime":1745574663408}}}